NCT01850641View on ClinicalTrials.gov

A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia

PHASE3CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 29, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 3, 2013

Conditions
HemodialysisHyperphosphatemia
Interventions
DRUG

PA21

Trial Locations (1)

Unknown

Multiple Locations

Sponsors
All Listed Sponsors
lead

Kissei Pharmaceutical Co., Ltd.

INDUSTRY

NCT01850641 - A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia | Biotech Hunter | Biotech Hunter